Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: A population-based study

Clinical Infectious Diseases

Volumn 43, Issue 10, 2006, Pages 1272-1276

  Lowe, Donna O ^a,f   Mamdani, Muhammad M ^b,e   Kopp, Alexander ^e   Low, Donald E ^a,b   Juurlink, David N ^b,c,d,e  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^f TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BACAMPICILLIN; CEFACLOR; CEFADROXIL; CEFALEXIN; CEFIXIME; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; CLINDAMYCIN; CLOXACILLIN; CORTICOSTEROID DERIVATIVE; COTRIMOXAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; HP PAC; IMMUNOSUPPRESSIVE AGENT; LANSOPRAZOLE; MACROLIDE; NITROFURANTOIN; OMEPRAZOLE; PANTOPRAZOLE; PENICILLIN DERIVATIVE; PIVAMPICILLIN; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RABEPRAZOLE; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; CANADA; CASE CONTROL STUDY; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; DRUG USE; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INFECTION RISK; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; POPULATION RESEARCH; PRIORITY JOURNAL;

AGED; ANTI-INFECTIVE AGENTS; CASE-CONTROL STUDIES; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HOSPITALIZATION; HUMANS; MALE; PROTON PUMPS;

EID: 33750689923     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/508453     Document Type: Article

References (40)

1. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989; 320:204-10.
2. Wheeler JG, Sethi D, Cowden JM, et al. Study of infectious intestinal disease in England: rates in the community, presenting to general practice, and reported to national surveillance. The Infectious Intestinal Disease Study Executive. BMJ 1999; 318:1046-50.
3. National Clostridium difficile Standards Group: report to the Department of Health. J Hosp Infect 2004; 56(Suppl 1):1-38.
4. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366:1079-84.
5. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353:2433-41.
6. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multiinstitutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353:2442-9.
7. Severe Clostridium difficile-associated disease in populations previously at low risk-four states, 2005. MMWR Morb Mortal Wkly Rep 2005; 54:1201-5.
8. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005; 173:1037-42.
9. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171:466-72.
10. Karlstrom O, Fryklund B, Tullus K, Burman LG. A prospective nationwide study of Clostridium difficile-associated diarrhea in Sweden. The Swedish C. difficile Study Group. Clin Infect Dis 1998; 26:141-5.
11. Riley TV, Wymer V, Bamford VW, Bowman RA. Clostridium difficile in general practice and community health. J Hyg (Lond) 1986; 96:13-7.
12. Kyne L, Merry C, O'Connell B, Keane C, O'Neill D. Community-acquired Clostridium difficile infection. J Infect 1998; 36:287-8.
13. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005; 294:2989-95.
14. Poutanen SM, Simor AE. Clostridium difficile-associated diarrhea in adults. CMAJ 2004; 171:51-8.
15. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect 1998; 40:1-15.
16. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330:257-62.
17. Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 1993; 17:109-13.
18. Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 1996; 39:54-9.
19. IMS Health. Leading 20 therapeutic classes by U.S. sales, 2005. Available at: http://www.imshealth.com/ims/portal/front/articleC/0,2777,6599_ 73915261_77140565,00.html. Accessed 1 August 2006.
20. Public Health Agency of Canada. Clostridium difficile (C. difficile): questions and answers. Available at: http://www.phac-aspc.gc.ca/c-difficile/ index.html. Accessed 1 August 2006.
21. Clostridium difficile-associated diarrhea (CDAD) and proton pump inhibitor therapy: CAG position statement. Canadian Association of Gastroenterology. Can J Gastroenterol 2005; 19:373-5.
22. Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003; 54:243-5.
23. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004; 171:33-8.
24. Shah S, Lewis A, Leopold D, Dunstan F, Woodhouse K. Gastric acid suppression does not promote clostridial diarrhoea in the elderly. QJM 2000; 93:175-81.
25. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41:1254-60.
26. Modena S, Bearelly D, Swartz K, Friedenberg FK. Clostridium difficile among hospitalized patients receiving antibiotics: a case-control study. Infect Control Hosp Epidemiol 2005; 26:685-90.
27. Al-Tureihi FI, Hassoun A, Wolf-Klein G, Isenberg H. Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients. J Am Med Dir Assoc 2005; 6:105-8.
28. Statistics Canada. Population by sex and age group, by province and territory. Available at: http://www40.statcan.ca/101/cst01/demo31a .htm?sdi=population%20sex%20age%20gropu%20provice%20territo ry. Accessed 1 August 2006.
29. Levy AR, O'Brien BJ, Sellors C, Grootendorst P, Willison D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol 2003; 10:67-71.
30. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351:543-51.
31. Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004; 363:1751-6.
32. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003; 289:1652-8.
33. Mamdani M, Rochon PA, Juurlink DN, et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 2002; 325:624.
34. International statistical classification of diseases and related health problems. 10th revision. Ottawa, Canada: Canadian Institute of Health Information, 2003.
35. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001; 154:854-64.
36. Schneeweiss S, Wang PS, Avorn J, Maclure M, Levin R, Glynn RJ. Consistency of performance ranking of comorbidity adjustment scores in Canadian and US utilization data. J Gen Intern Med 2004; 19:444-50.
37. Schneeweiss S, Wang PS, Avorn J, Glynn RJ. Improved comorbidity adjustment for predicting mortality in Medicare populations. Health Serv Res 2003; 38:1103-20.
38. Hirschhorn LR, Trnka Y, Onderdonk A, Lee ML, Platt R. Epidemiology of community-acquired Clostridium difficile-associated diarrhea. J Infect Dis 1994; 169:127-33.
39. Bashford JN, Norwood J, Chapman SR. Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database. BMJ 1998; 317:452-6.
40. Pham CQ, Regal RE, Bostwick TR, Knauf KS. Acid suppressive therapy use on an inpatient internal medicine service. Ann Pharmacother 2006; 40:1261-6.